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Abstract: Notwithstanding multimodal approaches including chemotherapeutic agents and radiation have been used for 
decades as major strategies to successfully treat cancer patients; however, the emergence of drug or radiation 
resistance led to a significant incidence of tumor relapse and hence limits their effectiveness. Therefore, the need for 
novel and effective strategies which are clinically vital; not only for improved efficacy to eliminate resistant tumor cells but 
also to permit less-toxic doses and potentially overcome resistance, was and still a hopeful goal. Natural killer (NK) cells 
comprise 5–10% of peripheral blood lymphocytes (PBLs). Owing to the fact that NK cells have an importance role in anti-
tumour immunity as demonstrated by several elegant studies, therefore, this NK-cell activity has been exploited as the 
basis of cancer immunotherapy strategies. Nevertheless, tumor cells can effectively escape NK cell-mediated apoptosis 
through a cocktail of different mechanisms. Thus, to enhance NK cell effector function against tumors, different 
approaches have been recently developed to achieve an ex vivo NK-cell enhancement. One adoptive transfer approach 
uses expanded allogeneic NK cells, which are MHC class I-resistant. A second approach uses stable allogeneic NK cell 
lines, which is more practical for large-scale production and safety. A third approach is the genetic modification of NK 
cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK 
cells can be derived from different sources, including peripheral or cord blood cells, stem cells or induced pluripotent 
stem cells (iPSCs). Here, we summarize the recent developments in genetic engineering of NK-cell-based 
biopharmaceuticals, and covering the usefulness, effectiveness, and safety for their clinical applications.  
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INTRODUCTION 
The immune system is honoured century ago to 
have the capacity to fight against tumours [1]; however, 
a well recognized hallmark of cancer is that the artful 
manner the cancer cells use to evade destruction by 
immune cells [2]. Immunotherapy is a novel promising 
approach for the treatment of malignant tumours. 
Titanic efforts are made to improve the use of 
immunotherapy against malignancies. Currently, there 
is a plethora of immunotherapy approaches; however, 
a general approach involves stimulating patient 
immune cells ex vivo to enhance an anti-tumour 
response when administered back into the patient. 
Current strategies are striving to improve anti-tumour 
responses to a wide spectrum of malignant tumours, by 
enhancing tumour antigen presentation to naive or 
memory T cells and activating other effector cells, such 
as natural killer (NK) cells [3]. It should not be 
forgotten, however that the ultimate goal in this 
odyssey is to protect patients from future tumour 
relapses by inducing a long-term memory response, 
while delaying or inhibiting tumour growth [4]. Until now 
there are three main branches of immunotherapy; non-
specific stimulation, active immunotherapy and 
adoptive transfer. Non-specific stimulation, such as  
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interleukin-2 (IL-2) or interferon-α (IFN-α) treatment, 
aims to enhance the immune system against cancer 
(e.g., melanoma and kidney cancer), however this 
treatment alone has shown to be ineffective [5]. Active 
immunotherapy provokes the host’s immune system to 
generate a response against the cancer, with the use 
of vaccination. Low toxicity and the potential of a 
lasting effect (cellular memory) are the major pros of 
this treatment; however the effectiveness of 
vaccinations remains varied [6]. The last branch is 
adoptive, or cell transfer immunotherapy, which 
involves isolating immune cells that can fight against 
cancer cells. These immune effector cells are growing 
and modifying ex vivo, and then adoptively transferring 
into the patients [7]. So far, a wide spectrum of 
therapeutic agents have been investigated in the 
cancer immunotherapy field, including cytokines, 
monoclonal antibodies, adoptive cell transfers (T, NK 
and NKT) and Toll-like receptor (TLR) agonists [8-10]. 
Indeed, adoptive transfer of NK cells has held great 
promise for over three decades since the original 
observation that isolated NK cells could kill malignant 
cells [11], and hence its use in the clinical trials as a 
powerful immunotherapy for the treatment of malignant 
diseases is ongoing [12].  
In this article, we will review the recent advances in 
genetic engineering of NK-cell-based 
biopharmaceuticals, and covering the usefulness, 
effectiveness, and safety for their clinical applications.  
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The NK cells: natural fighters against cancer 
cellsNK cells were initially abandoned when they 
regarded as an “experimental artifact” in T cell 
cytotoxicity assays. Rolf Kiessling and Eva Klein in 
1975 [11, 13], and Herberman and colleague [14, 15] 
were the first who discovered the NK cells in mice more 
than 35 years ago, and who also named them natural 
killer cells. The odyssey of identifying human NK cells 
starts with describing them as non-adherent, non-
phagocytic, FcγR+, large granular lymphocytes (LGL) 
[16]. However, later it was realized that not only NK 
cells shared the LGL phenotype but also some NK cells 
displayed normal small lymphocyte morphology, 
depending on their activation status [17]. NKR-P1 [18] 
and NK1.1 [19] antigens made it possible to define 
murine NK cells roughly as NK1.1+ TCR- sIg-CD16+. 
Today, human NK cells are defined as lymphocytes 
that are distinguished by CD3-CD56+. They comprise 
approximately 10-15% of all circulating lymphocytes 
and are also found in tissues, including the liver, and 
placenta. Resting NK cells that circulate in the blood 
are able to infiltrate into most tissues that contain 
pathogen-infected or malignant cells after their 
activation by cytokines [20]. 
Klas Kärre presented the first piece of the puzzle as 
the non-self hypothesis in 1981. He suggested that NK 
cells kill target cells lacking expression of self major 
histocompatability (MHC) class-I molecules although 
the mechanism was unclear at that time [21, 22]. This 
model was later confirmed by the discovery of inhibitory 
receptors on NK cells.  
Natural killer cells express both inhibitory and 
activating receptors, the immunoglobulin super family 
(killer-cell immunoglobulin-like receptors (KIR) and 
natural cytotoxicity receptors (NCR)) and the C-type 
lectin superfamily [23]. The balance of signals that NK 
cells receive will determine whether or not NK cells turn 
activated [24]. NK cells become activated when ligands 
expressed on tumor cells engaged the activating 
receptor, while keeping the inhibitory receptor 
unoccupied [23]. The ample evidence from a mouse 
xenograft tumor model demonstrated that NK cells can 
effectively eradicate tumor cells through direct or 
indirect mechanisms [25-28]. Direct mechanisms 
include cytoplasmic granule release [29], death 
receptor-induced apoptosis [30], effector molecule 
production (e.g. IFN-γ) [31] or antibody dependent 
cellular cytotoxicity (ADCC) [27]. Indirect mechanisms 
of killing tumor cells include the crosstalk between the 
NK cells and dendritic cells (DC) to enhance the tumor 
antigen uptake and presentation [32-34], and hence 
facilitating the generation of antigen-specific cytotoxic T 
lymphocytes (CTL) responses. Furthermore, IFN-γ 
produced by activated NK cells can induce switching of 
CD8+ T cells to CTLs, control differentiation of CD4+ T 
cells toward a Th1 response and promote CTL 
differentiation [35, 36]. A second role of the cytokines 
produced by activated NK cells might also orchestrate 
antitumor antibody production by B cells [27].  
THE NK CELLS AS AN ANTICANCER 
BIOPHARMACEUTICAL 
A biopharmaceutical is a pharmaceutical product 
that is biological in nature and manufactured using 
biotechnology [37]. Therefore, production of ex vivo NK 
cells and their use for the treatment of malignant 
diseases may be considered as an anticancer 
biopharmaceutical. Tumor cells use different pathways 
to escape from NK-cell recognition, such as silencing 
expression of adhesion molecules, ligands for 
activating receptors, up regulating MHC class I, soluble 
MIC, FasL, secreting immunosuppressive factors such 
as IL-10, TGF-β and resisting Fas- or perforin-
mediated apoptosis [38, 39]. Decreased cytotoxicity, 
defective expression of activating receptors, over 
expression of inhibitory receptors, defective 
proliferation, and defective cytokine production are 
hallmarks of NK cells abnormalities in cancer patients 
[31]. Therefore, NK-cell based immunotherapeutic 
strategies (Figure 1) have been proposed as an as an 
anticancer biopharmaceutical. A broad spectrum of 
various approaches has been applied from the use of 
monoclonal antibodies or recombinant cytokines to 
adoptive transfer of ex vivo activated or genetically 
modified donor NK cells [40].  
MODULATION OF ENDOGENOUS NK CELL 
ACTIVITY 
Early studies have been clearly shown that NK cell 
activation with IL-2 can enhance the proliferation and 
cytotoxic activity against NK-resistant targets that [41-
43]. Several elegant studies on animal models have 
supported further the efficiency of IL-2 treatment 
approach for cancer immunotherapy [44-53]. In the 
clinical setting, Rosenberg and colleagues [54, 55] 
have demonstrated the potent effect of IL-2 in the 
treatment of cancer patients by activating the 
cytotoxicity of the NK cells [56], and this effect is 
dependent on the dose and schedule of IL-2 
administration [57]. IL-2 has been attempted for the 
treatment of various tumor types, and was shown 
significantly increase number of circulating NK cells 
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and their cytotoxicity against different types of NK 
resistant cancers [58-63]. In addition, using a coktail IL-
2, IL-12, IL-15, IL-18, IL-21, and type I IFN have shown 
to stimulate NK cell cytotoxicity in vitro and show 
synergy when used in combination [64, 65]. Increase of 
the NK cell proliferation capacity, cytokine production, 
and up regulation of Kp44, perforin, granzymes, FasL 
expression are hallmarks of IL-2 therapy induced NK 
cell activity in cancer patients.85 Transferring of IL-2 
activated NK cells has showed greater success than 
the adminstering of IL-2 systemically [66-68].  
Overall, data from the reports demonstrated that 
notwithstanding IL-2 treatment is a promising 
approach, however is not the optimal strategy for 
treating cancer patients, and that combination therapy 
is needed. Furthermore, toxicity of IL-2 and induction of 
NK cell apoptosis by IL-2 are the dark face of the moon 
and can lead to a poor clinical outcome.  
ADOPTIVE TRANSFER OF NK CELLS 
In the clinical setting, the number, purity, and 
activation status of NK cells to be used are vital factors 
to be considered. The selection of NK cell isolation 
method from peripheral blood (PB) is crucial for normal 
expression of cell surface markers, intracellular 
cytokines, perforin and granzyme B, and preserving 
their proliferative and cytotoxic capacity, and therefore 
their use for adoptive immunotherapy [69-75]. Given 
that NK cells present in PB only in low number, 
therefore obtaining a large number of NK cells to be 
used in the clinical studies is a difficult task. Thus, 
many reports showed successful ex vivo expansion of 
NK cells for adoptive immunotherapy applications, and 
some of these NK cell-based products have already 
been used in the clinic, which showed to exert specific 
in vitro cytotoxic activity against different human tumor 
cells [75-89]. These studies clearly showed that every 
NK cell expansion protocol and every different donor 
does not yield expanded NK cells with similar 
phenotype. Thus, factors such as distribution of KIR 
expressing populations and expression of activating 
and inhibitory receptors are vital and need to be 
checked as they have a significant effect on the their 
clinical applicability and efficiency. 
ADOPTIVE TRANSFER OF AUTOLOGOUS NK 
CELLS 
Different animal studies revealed that adoptive 
transfer of NK cells proved to be efficient and 
successful [90]. Additionally, activated NK cells isolated 
from acute myeloid leukemia (AML) patients 
 
Figure 1: In vivo and ex vivo modulation of NK cell activity. 
Autologous (patient) or donor NK cells can be transferred to fight against the tumor cells after an in vivo or ex vivo 
manipulations. An in vivo modification of natural killer (NK) cell activity can be achieved through (A) infusion of cytokines and or 
(B) tumor specific monoclonal antibodies (MoAbs) to enhance the Antibody-dependent cellular cytotoxicity (ADCC) responses. 
The adoptive transfer of the ex vivo modified autologous or allogenic NK cells after short or long-term (C) expansion is another 
approach to eradicate the cancer cells. Genetic modification of NK cells (D) is a recent promise option.  
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demonstrated high cytotoxicity against autologous AML 
blasts in vivo in an NOD/SCID model [91]. Various 
clinical studies have investigated the impact of 
autologous NK cells infusion in different types of 
cancers on the clinical outcome. The clinical outcomes 
varied from no improvements to fully improved and 
complete remission (CR) of the patients [61, 77, 80, 86, 
92-94]. 
ADOPTIVE TRANSFER OF ALLOGENEIC NK 
CELLS 
Efficient adoptive transfer of allogenic NK cells 
requires absence of one or more killer immunoglobulin 
like receptors (KIR) ligands in the recipient but present 
in the donor. NK cells that express inhibitory KIR for 
which there is no ligand on recipient cells would give 
the best chances for anti-tumor reactivity and hence for 
clinical responses [95-97]. The greatest attention of 
using the KIR-ligand mismatched in the setting of NK 
cell-based immunotherapy occurred after the 
distinguished retrospective analysis of haplotype 
mismatched hematopoietic stem cell transplants 
(HSCT) by Ruggeri et al. which revealed delayed 
relapse, better engraftment and protection from graft 
versus host disease (GvHD) in leukemia patients [96, 
98]. Further studies have shown that NK cells from 
healthy donors and cancer patients have higher 
cytotoxic activity against various KIR-ligand 
mismatched tumor cell lines when compared to KIR-
ligand matched targets [99]. Several groups performed 
clinical trials with infusion of allogeneic NK cells.[72, 
97, 100-108] Of these studies, Shi et al. treated 10 
multiple myeloma (MM) patients with haploidentical NK 
cells before autlogous stem cell transplantation 
(ASCT), and interestingly found that the allogeneic NK 
cells survived in the PB of the patient at about 7 days 
until eventually they were undetectable by day 14. This 
finding has been confirmed by Miller et al who 
observed an in vivo expansion of the allogenic 
adoptively transferred NK cells, and a complete 
remission rate of 50% was also reported. This may 
indicate the clinical benefit of the adoptive allogenic NK 
cell trasfer without long-term engraftment, although the 
cells were undetectable after 14 days. NK cell lines 
such as 92287 are another alternative in NK cell-based 
tumor immunotherapy. This cell line lacks KIR but 
expresses several activating receptors [109]. NK-92 
cell line has been used in mouse studies [110, 111] 
and as direct infusions to patients [112, 113]. These 
experiments suggest that infusion of NK-92 may be 
safe and potentially beneficial. 
GENETIC MODIFICATION OF NK CELLS: A NEW 
NAVIGATION IN CANCER IMMUNOTHERAPY  
Gene Therapy 
The delivery of the gentic material (DNA or RNA) 
into target cells for the purpose of of preventing or 
treating a disease. The first gene transfer into human 
cells was described in 1990; a four-year old patient with 
adenosine deaminase deficiency was the first who 
received gene therapy [114]. This trial opened the door 
widely for many other gene therapy clinical trials with 
their highs and lows. A distinguished study by 
Rosenberg et al in 1990 has motivated the interest in 
genetically modifying immune effector cells in order to 
use them in cancer immunotherapy. Rosenberg and 
colleagues have ex vivo introduced the foreign genes 
into the hematopoitic cells to be adoptively later 
transferred [115]. Initially, T cells were the only 
investigated effector cells in the cancer 
immunotherapy; however, more players including NK 
cells are now considered as new “weapons of mass 
destruction” and hence great efforts are made to 
genetically engineering them for the cancer 
immunotherapy. 
Gene Delivery Vectors  
The delivery of the gene-of-interest (GOI) into the 
cell using viral vectors was launched in 1986 by Rogers 
and Pfuderer [116]. Since then, viruses have been 
widely used as gene delivery vehicles. Given that 
viruses vectors have the limitations of pathogenicity 
and immunogenicity; other researchers prefer to use 
non-viral delivery methods. Every method (viral versus 
non-viral) of delivering nucleic acids needs special 
considerations and has pros and cons [117, 118]. 
A defining feature of viral vectors vis-à-vis non-viral 
delivery of genes is that in general they are highly 
efficient. However, using viruses for gene delivery has 
its own cons. To overcome the virus pathogenicity and 
to ensure that the virus will not be replicating and 
spreading, all viral genes and sequences except those 
necessary for packaging of the viral genome are 
removed, and thus will leave a space for therapeutic 
genes to be inserted. Changing viral promoter 
elements and envelope proteins is highly 
recommended to enhance safety and ensure the 
tropism of the virus to the target cell type [119, 120]. 
The commonly used viral vectors include gamma 
retrovirus, lentivirus, adenovirus, or herpes vectors. 
Every vector has its own characteristics in terms of 
genome size, coating of the particle, infection mode, 
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persistence and immunogenicity. The high level of 
stable transgene expression and long term experience 
is the major advantages of the retroviral vectors. 
Contrary, a disadvantage of these vectors is that 
transduction can be performed only on efficiently 
dividing cells [121]. Lentiviral vectors are another type 
of gene delivery vectors which are capable of 
integrating also into non-dividing cells. The permanent 
gene expression and lower risk of damaging insertions 
are two features of the lentiviral vectors; however, an 
integration bias without oncogenic selection has 
recently been reported [122]. 
Genetic Modification of NK Cells 
Gene transfer into NK cells may pave the way for 
new opportunities for the immunotherapy cancer in 
both autologous and allogeneic settings. The 
introduction of chimeric antigen receptors (CAR) is very 
recently stepping on the scene as a novel means of 
genetically modifying NK cells to redirect them to attack 
the tumor targets, and investigations are ongoing to 
use them for clinical applications [123]. Furthermore, 
induction of NK cell proliferation or survival using 
cytokine gene therapy is an additional approach of 
genetic engineering of NK cells [124]. Stable 
transduction using retroviral [124-129] or lentiviral [130-
136] vectors is preferred over the transient methods 
such as electroporation [123, 137, 138] or 
nucleofection [139] in terms of long-term effects. Liu et 
al. have demonstrated that transfection of the CD18 
gene into the CD18-deficient NK cell line (YT-1) causes 
restoration of the cytotoxic capacity of the cell line 
against a B cell lymphoma line [140]. Another study 
showed that upon genetic modification of the NK cell 
lines with the IL-15 gene leads to increases in the 
proliferative rate and cytotoxic capacity [141, 142]. IL-
12 is another cytokine gene therapy in which the gene 
was transferred into mouse NK cells which results in an 
increased in their survival capacity and in vivo anti-
tumor activity [143]. Activation of T cells which 
increases the chance of GvHD [144] and stimulation of 
immunosuppressive T regulatory cells [145] are both 
unwelcomed side effects of the systemic IL-2 
administration [146, 147]. Since IL-2 is a potent 
enhancer of the NK cells and to avoid the unwelcomed 
IL-2 side effects, IL-2 gene was transduced into the NK 
cell lines (e.g., NK-92 )[124, 148] and an increased in 
the cytotoxic activity against tumor cell lines in vitro 
was observed. This manipulation of NK92 cells enabled 
them to secrete IL-2 independently on an exogenous 
feeding, and the cells showed an increased in the 
proliferation capacity and antitumor activity in mice 
models [124, 149]. However, the risk of activating other 
immune effector cells by secreted IL-2 from the 
transduced NK cells still remains, and therefore a study 
investigated an alternative approach for IL-2 delivery by 
keeping the effect only in NK cells in a controlled and 
localized manner [129]. This approach may be useful 
for the future engineering of the NK cells. Another 
approach to reprogram the NK cells for cancer 
immunotherapy is the CAR receptor expression on the 
NK cells, which enhances the NK cell activity through 
retargeting of the NK cells to tumor cells. Generally a 
single-chain variable fragment receptor specific for a 
certain tumor-associated antigen and is fused to the 
intracellular signalling moiety CD3ζ chain. This 
approach has been used by several groups and proved 
an effective tactic to increase the NK cell reactivity 
against different tumor antigens. Chimeric receptors 
against CEA [150], CD33 [151], and Her2/neu [128, 
152, 153], have been successfully delivered to NK cell 
lines and were displayed to markedly increased NK cell 
cytotoxicity both in vitro and in vivo. To further extend 
the importance of these findings, Pegram et al. have 
reprogrammed the gene of primary mouse cells to 
express a chimeric receptor against Her2/neu and 
found that the adoptive transfer of these cells to mice 
bearing Her2+ tumors inhibits tumor progression in vivo 
[154]. Kruschinski et al. have also reprogrammed 
primary NK cells from human donors to express a 
chimeric receptor against Her2/neu and observed high 
cytotoxic activity against Her2+ cell lines both in vitro 
and in xenograft models with RAG2-/- mice [155]. In 
addition, Imai et al. have found that reprogramming of 
autologous NK cells to express a chimeric receptor 
against CD19; a molecule widely expressed by 
malignant B cells, results in efficient killing of 
autologous leukemic cells in vitro [156]. Transduction of 
NK-92-MI cells with a CAR (CD138); a highly 
expressed antigen on multiple myeloma (MM) cells, 
has been shown to significantly enhance the anti-MM 
efficacy of NK cells, and the first to be tested in the 
clinical trials [157]. Taken together, these data indicate 
a new avenue of the adoptive transfer of chimeric 
antigen-specific bearing NK cells, which proved at least 
in vitro to enhance the NK cytotoxic abilities, and thus 
might be a novel navigation in the field of cancer 
immunotherapy. However, limitations such as efficiency 
of gene delivery to NK cells and safety of the vectors 
are still challenging for their clinical applications. 
CONCLUSIONS 
Notwithstanding that NK cell based therapies 
showed little clinical success, but it still holds great 
promise for the treatment of cancer patients. Better 
understanding of the NK cell biology and function will 
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open new vistas to reprogram the NK cells to enhance 
the NK cytotoxic functions, and thus might be a novel 
navigation in the field of cancer immunotherapy. 
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